<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Petra Feyer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Jordan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Schild, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nausea and vomiting caused by radiotherapy (RT) are generally less severe than that caused by chemotherapy, but nausea and vomiting can last for a prolonged period in some cases. These side effects are clinically important and can be distressing for patients. Furthermore, RT-induced nausea and vomiting (RINV) can cause patients to delay or refuse further treatment.</p><p>The incidence, classification of risk, and management of RINV are discussed here. The approach to chemotherapy-induced nausea and vomiting is discussed separately. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of RINV is incompletely understood but is thought to be similar to that caused by chemotherapy. Progress in understanding the pathophysiology of chemotherapy-induced emesis led to the development of agents that form the basis for treatment of RINV. (See  <a class="medical medical_review" href="/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Two prospective observational studies provide information on the frequency of RINV and the extent to which this problem is treated:</p><p class="bulletIndent1"><span class="glyph">●</span>The Italian Group for Antiemetic Research in Radiotherapy (IGARR) analyzed the incidence of RINV in 1020 patients receiving various kinds of RT with or without concomitant chemotherapy [<a href="#rid1">1</a>]. Overall, nausea and/or vomiting was reported by 28 percent. The median time to the first episode of vomiting was three days. Antiemetic drugs were administered to 17 percent of the patients, including 12 percent treated prophylactically and 5 percent given rescue therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another series of 368 patients receiving RT with or without concomitant chemotherapy, the overall incidence rates for nausea and vomiting were 39 and 7 percent, respectively [<a href="#rid2">2</a>]. Nausea was more frequent in those receiving RT to the lower abdomen or pelvis and to the head and neck area (66 and 48 percent, respectively). Importantly, only one-fourth of the patients reporting nausea felt that antiemetics had been beneficial, and one-third would have liked additional treatment.</p><p></p><p>The importance of RINV is illustrated by its impact on quality of life (QOL). In an analysis of patients receiving abdominal RT, a patient's subjective experiences from RINV directly correlated with the worsening of QOL outcomes [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4"><span class="h1">RISK CLASSIFICATION</span><span class="headingEndMark"> — </span>The incidence and severity of RINV depend upon details of the treatment (irradiated site and volume, single and total dose, fractionation schedule, techniques). Patient-related factors (sex, general health of the patient, age, concurrent or recent chemotherapy, psychological state, tumor stage, history of prior treatment-related nausea) are also important.</p><p>Radiation induced nausea is likely secondary to irradiation of the stomach and small intestines, causing irritation or stimulation. The most important factor appears to be the radiation field. The 2016 guidelines from the Multinational Association for Supportive Care in Cancer (MASCC) and European Society for Medical Oncology (ESMO), which have been subsequently endorsed by the American Society of Clinical Oncology (ASCO), divide the risk of emesis due to radiation therapy into four categories  (<a class="graphic graphic_table graphicRef119996" href="/d/graphic/119996.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119997" href="/d/graphic/119997.html" rel="external">table 2</a>) [<a href="#rid4">4-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High – Total body irradiation</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Upper abdominal irradiation, craniospinal</p><p class="bulletIndent1"><span class="glyph">●</span>Low – Cranium (all), head and neck, thorax, pelvis</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal – Breast and extremities</p><p></p><p class="headingAnchor" id="H5"><span class="h1">PREVENTION AND TREATMENT</span><span class="headingEndMark"> — </span>There are only limited data from randomized trials that have evaluated the efficacy of various antiemetic drugs in preventing RINV  (<a class="graphic graphic_table graphicRef82679" href="/d/graphic/82679.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef73445" href="/d/graphic/73445.html" rel="external">table 4</a>). Generally, these trials were conducted in patients at moderate or high risk for RINV. </p><p>The available evidence from these trials indicates that 5-hydroxytryptamine (5-HT3) receptor antagonists are the most active agents that have been evaluated in randomized trials. However, other agents also have a role in some settings, especially in patients receiving concomitant chemoradiotherapy. (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">5-HT3 receptor antagonists</span><span class="headingEndMark"> — </span>The results with 5-HT3 receptor antagonists were analyzed in a meta-analysis that included nine trials [<a href="#rid7">7</a>]. In this meta-analysis, fewer patients had residual emesis compared with placebo (40 versus 57 percent, relative risk [RR] 0.7, 95% CI 0.57-0.86), and fewer required rescue medication (6.5 versus 36 percent, RR 0.18, 95% CI 0.05-0.60). Despite antiemetic prophylaxis, most patients did develop RT-induced nausea (70 versus 83 percent with placebo, RR 0.84, 95% CI 0.73-0.96). </p><p>The underlying incidence of nausea and vomiting in these trials is heavily influenced by the study populations  (<a class="graphic graphic_table graphicRef82679" href="/d/graphic/82679.html" rel="external">table 3</a>). Taken together, these trials show that 5-HT3 receptor antagonists have significantly greater protective effect against RINV for patients receiving upper abdomen irradiation than <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, phenothiazines, or placebo [<a href="#rid8">8-13</a>]. Similarly, 5-HT3 receptor antagonists provided significantly better protection against RINV caused by total body irradiation or hemibody irradiation than conventional antiemetics or placebo  (<a class="graphic graphic_table graphicRef73445" href="/d/graphic/73445.html" rel="external">table 4</a>) [<a href="#rid14">14-18</a>]. Separate analyses of trials comparing 5-HT3 receptor antagonists with metoclopramide also demonstrated a statistically significant benefit for the control of vomiting.</p><p>The adverse effects of 5-HT3 receptor antagonists are generally mild, consisting mainly of headache, constipation, diarrhea, and asthenia [<a href="#rid13">13,14,16,19,20</a>]. In some patients, 5-HT3 receptor antagonists reduced the frequency of diarrhea, a troublesome side effect due to acute radiation enterotoxicity [<a href="#rid10">10,21</a>].</p><p>Randomized trials in RINV have utilized five different 5-HT3 receptor antagonists (<a class="drug drug_general" data-topicid="9944" href="/d/drug information/9944.html" rel="external">palonosetron</a>, <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>, <a class="drug drug_general" data-topicid="8501" href="/d/drug information/8501.html" rel="external">granisetron</a>, <a class="drug drug_general" data-topicid="8592" href="/d/drug information/8592.html" rel="external">dolasetron</a>, tropisetron). These agents have not been compared with each other, and there are inadequate data to define optimal doses and schedules [<a href="#rid7">7</a>]. Except for very small trials, the data with palonosetron are limited to a chemoradiotherapy trial in which palonosetron was administered weekly before <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid22">22,23</a>].</p><p>The injected formulation of <a class="drug drug_general" data-topicid="8592" href="/d/drug information/8592.html" rel="external">dolasetron</a> is contraindicated for prophylaxis of RINV due to the risk of QTc prolongation from increased drug exposure [<a href="#rid24">24</a>]. Although the risk of developing an abnormal heart rhythm with oral dolasetron is less than that seen with the injection form, precautions are indicated to avoid arrhythmias, even with the oral formulation. (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Dolasetron'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Corticosteroids</span><span class="headingEndMark"> — </span>Corticosteroids are an attractive option because of their widespread availability, low cost, and activity as antiemetics. </p><p>One randomized trial showed that <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> was significantly more effective than placebo in patients receiving RT to the upper abdomen [<a href="#rid25">25</a>]. A separate randomized trial demonstrated that steroids also can prevent flair of pain when irradiating bone metastases [<a href="#rid26">26</a>], in addition to helping with nausea. Corticosteroids are often used in patients with brain metastases for management of vasogenic edema, and are also useful in managing RINV. (See  <a class="medical medical_review" href="/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors", section on 'Initiation of glucocorticoids'</a>.)</p><p>Combining corticosteroids with 5-HT3 receptor antagonists was assessed in a trial in which a five-day course of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> plus <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> was compared with ondansetron plus placebo in 211 patients who received RT to the upper abdomen [<a href="#rid27">27</a>]. During the first five days, there was a statistically nonsignificant trend toward complete control of nausea (50 versus 38 percent with placebo) and vomiting (78 versus 71 percent), which was the primary objective of the trial. The effects of dexamethasone extended beyond the initial five-day period, and significantly more patients had complete control of emesis over the entire course of radiotherapy (23 versus 12 percent with placebo), a secondary objective of the trial. Although this study did not demonstrate a statistically significant benefit for the primary endpoint, the results strongly suggest that the addition of dexamethasone was beneficial.</p><p>Since emesis is more frequent early in treatment, prophylactic antiemetics may not be necessary for a full course of RT, and treatment for the first week may be sufficient [<a href="#rid25">25,28,29</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Neurokinin-1 receptor antagonists</span><span class="headingEndMark"> — </span>Neurokinin-1 (NK-1) receptor antagonists have an established role in the management of chemotherapy-induced nausea and vomiting (CINV). (See  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults", section on 'Neurokinin-1 receptor antagonists'</a>.)</p><p>None of the NK-1 receptor antagonists have been adequately evaluated in patients at risk for RINV when RT is given without concomitant chemotherapy. However, these agents have been evaluated for patients receiving concomitant chemoradiotherapy. [<a href="#rid30">30</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>An observational study in patients receiving concomitant chemoradiotherapy compared the combination of <a class="drug drug_general" data-topicid="9305" href="/d/drug information/9305.html" rel="external">aprepitant</a>, a 5-HT3 receptor antagonist, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> versus a 5-HT3 receptor antagonist and dexamethasone alone [<a href="#rid31">31</a>]. The three-drug combination showed a clinically meaningful benefit compared with the 5-HT3 receptor antagonist and dexamethasone alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a double-blind trial (GAND-emesis study), patients with cervical cancer were treated with fractionated RT plus weekly <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, using <a class="drug drug_general" data-topicid="9944" href="/d/drug information/9944.html" rel="external">palonosetron</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, with or without <a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">fosaprepitant</a>, to prevent RINV [<a href="#rid32">32</a>]. Patients receiving fosaprepitant in addition to palonosetron and dexamethasone were less likely to experience nausea and emesis compared with those receiving palonosetron and dexamethasone alone. </p><p></p><p class="headingAnchor" id="H9"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Older, less-specific antiemetic drugs such as <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>, <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a>, and cannabinoids have shown limited efficacy in the prevention or treatment of RINV, although they may have a role in patients with milder symptoms [<a href="#rid33">33</a>]. </p><p>The atypical neuroleptic <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> was investigated in a randomized trial of patients treated with fractionated RT and concomitant <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid34">34</a>]. Patients received olanzapine (10 mg) or <a class="drug drug_general" data-topicid="9032" href="/d/drug information/9032.html" rel="external">fosaprepitant</a> (150 mg on day 1) in combination with <a class="drug drug_general" data-topicid="9944" href="/d/drug information/9944.html" rel="external">palonosetron</a> and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>. The complete response rate was similar for the olanzapine regimen and the fosaprepitant regimen. In the delayed and overall periods, the olanzapine regimen was significantly better than the fosaprepitant regimen.</p><p class="headingAnchor" id="H10"><span class="h2">Duration of prophylaxis</span><span class="headingEndMark"> — </span>The appropriate duration of antiemetic prophylaxis for patients receiving fractionated RT is not clear and is still under study. A systematic review that included 25 randomized and nonrandomized trials found that 5-HT3 receptor antagonists were most commonly administered for the entire duration of a course of RT [<a href="#rid35">35</a>]. The decision on whether or not to continue antiemetic prophylaxis beyond the first week should be based upon an assessment of the risk of emesis as well as relevant individual factors. For example, for those receiving total body irradiation, we typically continue antiemetic prophylactic therapy on days of RT, as well as the day after each day of RT, if radiation is not planned for that day [<a href="#rid36">36</a>]. For other types of radiation, we typically do not include antiemetic prophylactic therapy on the day following treatment days, but rather on days of radiation therapy only  (<a class="graphic graphic_table graphicRef119996" href="/d/graphic/119996.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119997" href="/d/graphic/119997.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H11"><span class="h2">Rescue therapy</span><span class="headingEndMark"> — </span>The benefits of 5-HT3 receptor antagonists once nausea or vomiting occurs has been suggested in all studies, but there are no trials specifically in this setting [<a href="#rid37">37-39</a>]. The role of rescue medication for patients at low and minimal risk of RINV needs to be defined in further studies. The emerging role of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> in breakthrough emesis in patients with CINV has not been studied in RINV yet [<a href="#rid40">40</a>]; however, it is probable that olanzapine is beneficial in this setting. </p><p class="headingAnchor" id="H12"><span class="h1">PATIENT-SPECIFIC FACTORS</span><span class="headingEndMark"> — </span>The risk of nausea and vomiting for a patient being treated with RT depends upon multiple other factors in addition to the emetogenicity of the specific RT regimen (ie, higher daily doses of radiation to the intestines increases nausea). Patient-specific factors include the simultaneous administration of chemotherapy, age, sex, alcohol consumption, anxiety, and previous experience of nausea and vomiting [<a href="#rid29">29,41,42</a>].</p><p>The risk categories based upon the RT regimen can be modified to incorporate these patient-specific factors. Although not prospectively proven, an approach taking these risk factors into account might further improve emesis prophylaxis in patients receiving RT  (<a class="graphic graphic_figure graphicRef70623" href="/d/graphic/70623.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H14793961"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16303.html" rel="external">"Patient education: Nausea and vomiting with cancer treatment (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Radiotherapy (RT)-induced nausea and vomiting (RINV) is a frequent complication of RT. Its incidence and severity are influenced by the specific RT regimen, region treated, and patient-specific factors  (<a class="graphic graphic_table graphicRef119996" href="/d/graphic/119996.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119997" href="/d/graphic/119997.html" rel="external">table 2</a>). Patients should receive antiemetic prophylaxis based upon an individualized assessment of risk, taking into account both the planned RT regimen and patient-specific factors. (See <a class="local">'Risk classification'</a> above and <a class="local">'Patient-specific factors'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients at high risk of developing RINV  (<a class="graphic graphic_table graphicRef119996" href="/d/graphic/119996.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119997" href="/d/graphic/119997.html" rel="external">table 2</a>), we recommend prophylaxis with a 5-hydroxytryptamine (5-HT3) receptor antagonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Based upon results from patients receiving highly emetogenic chemotherapy, we suggest the addition of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> to the 5-HT3 receptor antagonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). There are no comparative clinical trials data on the use of neurokinin-1 (NK1) receptor antagonists in preventing RINV. However, in patients receiving concomitant chemoradiotherapy with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, the addition of an NK-1 receptor antagonist proved to be beneficial and should be the standard of care. (See <a class="local">'Risk classification'</a> above and  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients at moderate risk of developing RINV  (<a class="graphic graphic_table graphicRef119996" href="/d/graphic/119996.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119997" href="/d/graphic/119997.html" rel="external">table 2</a>), we recommend prophylaxis with a 5-HT3 receptor antagonist (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). In this risk group, we suggest the addition of a short course of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> to the 5-HT3 receptor antagonist during fractions 1 to 5 (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Risk classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients at low or minimal risk of developing RINV  (<a class="graphic graphic_table graphicRef119996" href="/d/graphic/119996.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef119997" href="/d/graphic/119997.html" rel="external">table 2</a>), we suggest <strong>not</strong> treating prophylactically (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). If patients develop RINV, options include a 5-HT3 receptor antagonist, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, or dopamine receptor antagonist. For patients treated with RT to the brain with RINV, we suggest dexamethasone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Risk classification'</a> above and <a class="local">'Patient-specific factors'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients being treated with concomitant RT and chemotherapy, antiemetic prophylaxis should be based upon the higher chemotherapy or RT risk category. (See <a class="local">'Patient-specific factors'</a> above and  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Maranzano E, De Angelis V, Pergolizzi S, et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 2010; 94:36.</a></li><li><a class="nounderline abstract_t">Enblom A, Bergius Axelsson B, Steineck G, et al. One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 2009; 17:23.</a></li><li><a class="nounderline abstract_t">Poon M, Hwang J, Dennis K, et al. A novel prospective descriptive analysis of nausea and vomiting among patients receiving gastrointestinal radiation therapy. Support Care Cancer 2016; 24:1545.</a></li><li><a class="nounderline abstract_t">Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.</a></li><li><a class="nounderline abstract_t">Ruhlmann CH, Jahn F, Jordan K, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. Support Care Cancer 2017; 25:309.</a></li><li><a class="nounderline abstract_t">Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27:v119.</a></li><li><a class="nounderline abstract_t">Salvo N, Doble B, Khan L, et al. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 2012; 82:408.</a></li><li><a class="nounderline abstract_t">Aass N, Håtun DE, Thoresen M, Fosså SD. Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 1997; 45:125.</a></li><li><a class="nounderline abstract_t">Bey P, Wilkinson PM, Resbeut M, et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 1996; 4:378.</a></li><li><a class="nounderline abstract_t">Franzén L, Nyman J, Hagberg H, et al. A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy. Ann Oncol 1996; 7:587.</a></li><li><a class="nounderline abstract_t">Lanciano R, Sherman DM, Michalski J, et al. The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Invest 2001; 19:763.</a></li><li><a class="nounderline abstract_t">Priestman TJ, Roberts JT, Lucraft H, et al. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol (R Coll Radiol) 1990; 2:71.</a></li><li><a class="nounderline abstract_t">Priestman TJ, Roberts JT, Upadhyaya BK. A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol (R Coll Radiol) 1993; 5:358.</a></li><li><a class="nounderline abstract_t">Prentice HG, Cunningham S, Gandhi L, et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15:445.</a></li><li><a class="nounderline abstract_t">Spitzer TR, Bryson JC, Cirenza E, et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12:2432.</a></li><li><a class="nounderline abstract_t">Spitzer TR, Friedman CJ, Bushnell W, et al. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 2000; 26:203.</a></li><li><a class="nounderline abstract_t">Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5:500.</a></li><li><a class="nounderline abstract_t">Tiley C, Powles R, Catalano J, et al. Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation. Leuk Lymphoma 1992; 7:317.</a></li><li><a class="nounderline abstract_t">Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist 2002; 7:424.</a></li><li><a class="nounderline abstract_t">Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61:162.</a></li><li><a class="nounderline abstract_t">Feyer PC, Stewart AL, Titlbach OJ. Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 1998; 6:253.</a></li><li><a class="nounderline abstract_t">Ruhlmann CH, Belli C, Dahl T, Herrstedt J. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study. Support Care Cancer 2013; 21:3425.</a></li><li><a class="nounderline abstract_t">Ganesh V, Chan S, Zhang L, et al. Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study. Ann Palliat Med 2018; 7:385.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA Drug Safety Communication: Abnormal heart rhythms associated with use of dolasetron mesylate. http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm (Accessed on December 21, 2010).</li><li><a class="nounderline abstract_t">Kirkbride P, Bezjak A, Pater J, et al. Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 2000; 18:1960.</a></li><li><a class="nounderline abstract_t">Chow E, Meyer RM, Ding K, et al. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16:1463.</a></li><li><a class="nounderline abstract_t">National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, et al. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 2006; 24:3458.</a></li><li><a class="nounderline abstract_t">American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24:2932.</a></li><li><a class="nounderline abstract_t">Feyer PCh, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer 2005; 13:122.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Nohara K, Furuya T, Yamatodani A. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav 2005; 82:24.</a></li><li><a class="nounderline abstract_t">Jahn F, Riesner A, Jahn P, et al. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. Int J Radiat Oncol Biol Phys 2015; 92:1101.</a></li><li><a class="nounderline abstract_t">Ruhlmann CH, Christensen TB, Dohn LH, et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 2016; 17:509.</a></li><li><a class="nounderline abstract_t">Roila F, Ciccarese G, Palladino MA, De Angelis V. Prevention of radiotherapy-induced emesis. Tumori 1998; 84:274.</a></li><li><a class="nounderline abstract_t">Navari RM, Nagy CK, Le-Rademacher J, Loprinzi CL. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 2016; 14:141.</a></li><li><a class="nounderline abstract_t">Dennis K, Zhang L, Lutz S, et al. International patterns of practice in the management of radiation therapy-induced nausea and vomiting. Int J Radiat Oncol Biol Phys 2012; 84:e49.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020; 38:2782.</a></li><li><a class="nounderline abstract_t">LeBourgeois JP, McKenna CJ, Coster B, et al. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol) 1999; 11:340.</a></li><li><a class="nounderline abstract_t">Maranzano E, Feyer PCh, Molassiotis A, et al. Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol 2005; 76:227.</a></li><li><a class="nounderline abstract_t">Mystakidou K, Katsouda E, Linou A, et al. Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients. Med Oncol 2006; 23:251.</a></li><li><a class="nounderline abstract_t">Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013; 21:1655.</a></li><li><a class="nounderline abstract_t">Jordan K, Kinitz I, Voigt W, et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009; 45:1184.</a></li><li><a class="nounderline abstract_t">Maranzano E. Radiation-induced emesis: a problem with many open questions. Tumori 2001; 87:213.</a></li></ol></div><div id="topicVersionRevision">Topic 7052 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19963296" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528717" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26377308" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A novel prospective descriptive analysis of nausea and vomiting among patients receiving gastrointestinal radiation therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947834" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiemetics: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27624464" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664248" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21075553" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424001" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883232" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879372" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A randomised placebo controlled study with ondansetron in patients undergoing fractionated radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11768028" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The efficacy and safety of once-daily Kytril (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1702012" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8305355" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599570" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Granisetron in the prevention of irradiation-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964960" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918432" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9406364" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1493431" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12401905" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17208005" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparative activity of antiemetic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629879" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Aetiology and prevention of emesis induced by radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23949739" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30180723" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30180723" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10784638" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26489389" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849762" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16717289" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592688" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098569" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26059352" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26952945" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620257" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevention of radiotherapy-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27152512" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704982" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : International patterns of practice in the management of radiation therapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32658626" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antiemetics: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10591823" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150504" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence-based recommendations for the use of antiemetics in radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16720926" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prophylactic tropisetron versus rescue tropisetron in fractionated radiotherapy to moderate or high emetogenic areas: a prospective randomized open label study in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23314603" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135359" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693797" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Radiation-induced emesis: a problem with many open questions.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
